Newamsterdam Pharma Company N.V. WT (NAMSW)

$8.90 +0.26 (3.01%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	N/A
Revenue (ttm)	14.09M
Net Income (ttm)	-176.94M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	500
Avg Vol	4,306
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	46%
Beta	N/A
Analysts	Strong Sell
Price Target	N/A

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease...

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands